Browse All

Current Filters

CLEAR FILTER x

TITLE

Long-term Safety and Efficacy of Zilucoplan in Myasthenia Gravis: Additional Interim Analyses of RAISE-XT

Author:Howard, James F.   Freimer, Miriam   Genge, Angela   Hewamadduma, Channa   Hussain, Yessar   Maniaol, Angelina   Mantegazza, Renato   Smilowski, Marek   Utsugisawa, Kimiaki   Vu, Tuan   Weiss, Michael   Duda, Petra   Boroojerdi, Babak   Vanderkelen, Mark   De La Borderie, Guillemette   Leite, M. Isabel   

Session Name:S15: Autoimmune Neuromuscular Diseases: New Observations and Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S15.002  

Author Institution:Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, Chapel Hill, NC  Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA, Columbus, OH  Clinical Research Unit, The Montreal Neurological Institute, Montreal, QC, Canada, Montreal, QC, Canada  Academic Neuroscience Unit, Sheffield Teaching Hospitals Foundation Trust, Sheffield, UK  Sheffield Institute for Translational Neurosciences (SITRAN), University of Sheffield, Sheffield, UK, Sheffield, United Kingdom  Department of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA, Austin, TX  Department of Neurology, Oslo University Hospital, Oslo, Norway, Oslo, Norway  Department of Neuroimmunology and Neuromuscular Diseases, Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy, Milan, Italy  Medical University of Silesia, Katowice, Poland, KATOWICE, Poland  Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan, Hanamaki, Japan  Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA, Tampa, FL  Department of Neurology, University of Washington Medical Center, Seattle, WA, USA, Seattle, WA  UCB Pharma, Cambridge, MA, USA, Cambridge, MA  UCB Pharma, Monheim, Germany, Monheim, Germany  UCB Pharma, Braine-l’Alleud, Belgium, Braine L'Alleud, Belgium  UCB Pharma, Brussels, Belgium, Brussels, Belgium  Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK , Oxford, United Kingdom  

The Safety and Efficacy of Chronic Weekly Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis (MG0004)

Author:Bril, Vera   Druzdz, Artur   Grosskreutz, Julian   Habib, Ali A.   Kaminski, Henry J.   Mantegazza, Renato   Sacconi, Sabrina   Utsugisawa, Kimiaki   Vu, Tuan   Boehnlein, Marion   Woltering, Franz   Greve, Bernhard   Gayfieva, Maryam   Vissing, John   

Session Name:P4: Autoimmune Neurology: Peripheral Autoimmunity  

Topic:Autoimmune Neurology  

Program Number:P4.017  

Author Institution:University Health Network, Toronto, ON, Canada, Toronto, ON, Canada  Department of Neurology, Municipal Hospital, Poznan, Poland, Swarzedz, Poland  Precision Neurology, Department of Neurology, University of Lübeck, Lübeck, Germany, Lubeck, Germany  MDA ALS and Neuromuscular Center, University of California, Irvine, Irvine, CA, USA, Orange, CA  Department of Neurology & Rehabilitation Medicine, George Washington University, Washington, DC, USA, Washington, DC  Department of Neuroimmunology and Neuromuscular Diseases, Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy, Milan, Italy  Université Côte d’Azur, Peripheral Nervous System & Muscle Department, Pasteur 2 Hospital, Centre Hospitalier Universitaire de Nice, Nice, France, Nice, France  Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan, Hanamaki, Japan  Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA, Tampa, FL  UCB Pharma, Monheim, Germany, Monheim, Germany  UCB Pharma, Monheim, Germany, Monheim Am Rhein, Germany  UCB Pharma, Slough, UK, London, United Kingdom  Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, Copenhagen, Denmark  

Long-term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Participants with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study

Author:Howard, James   Li, Yuebing   Vu, Tuan   Korobko, Denis   Steeland, Sophie   Van Hoorick, Benjamin   Podhorna, Jana   Hodari, Moana   Utsugisawa, Kimiaki   Sacca, Francesco   Wiendl, Heinz   De Bleecker, Jan   Mantegazza, Renato   

Session Name:P10: Neuromuscular and Clinical Neurophysiology (EMG): Myasthenia Gravis 3  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P10.008  

Author Institution:Department of Neurology, The University of North Carolina, Chapel Hill, North Carolina, Chapel Hill, NC  Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, Florida, Tampa, FL  State Budgetary Healthcare Institution of Novosibirsk Region "State Novosibirsk Regional Clinical Hospital," Novosibirsk, Russia, Novosibirsk, Russian Federation  argenx, Ghent, Belgium, Ghent, Belgium  argenx, Ghent, Belgium, Ghent , Belgium  argenx, Ghent, Belgium, Wiesbaden, Germany  argenx, Ghent, Belgium, Camberley, United Kingdom  Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan, Hanamaki, Japan  NRSO Department, Federico II University of Naples, Naples, Italy, Napoli, Italy  Department of Neurology, University of Münster, Münster, Germany, Muenster, Germany  Ghent University Hospital, Ghent, Belgium , Gent, Belgium  Department of Neuroimmunology and Neuromuscular Diseases, Fondazione Istituto Neurologico Carlo Besta, Milan, Italy, Milan, Italy